ArticleJournal of molecular histology2025
RBM15 promotes m6A methylation and stability of KLF6 mRNA to accelerate pyroptosis of retinal ganglion cells in early-stage diabetic retinopathy.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ruminococcaceae promotes the NLRP3/ASC/Caspase-1 axis-mediated pyroptotic signaling in papillary thyroid carcinoma by upregulating RBM15 to increase the N6-methyladenosine methylation modulation of NLRP3.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neurodegeneration in early-stage diabetes retinopathy (DR) is mainly caused by the loss of retinal ganglion cells (RGCs), and high glucose-treated cell pyroptosis contributes to an important cause. However, the detailed molecular regulatory mechanism has not yet been thoroughly examined. In this study, primary mouse RGCs were stimulated with different concentrations of glucose, and mouse was intraperitoneally injected with streptozotocin (STZ) to construct DR model in vitro and in vivo. We found that compared to normal controls, RNA binding motif protein 15 (RBM15) was significantly upregulated in high glucose-treated RGCs and STZ-induced mice. RBM15 silence restored cell viability and inhibited cell apoptosis and cell death in high glucose-triggered RGCs. In parallel, RBM15 knockdown distinctly improved pathological damage such as thinning of retinal tissue thickness and loss of RGCs in STZ-modeling mice. Interestingly, the production of inflammatory cytokines and the expression of Cleaved caspase-1, NLRP3 and GSDMD-N were significantly reduced by RBM15 silence in vivo and in vitro. Mechanistically, RBM15 bound to kruppel like factor 6 (KLF6) mRNA to promote m6A modification and stabilize KLF6 mRNA, upregulating KLF6 expression in model cells and model mice retinal tissues. KLF6 overexpression increased the production of inflammatory cytokines and the expression of proteins related to pyroptosis, reversing the protective effects of RBM15 silence in high glucose-treated RGCs and diabetic retina. In conclusion, RBM15 is upregulated by high glucose, and stabilizes KLF6 mRNA to activate NLRP3-mediated pyroptosis pathway, exacerbating inflammation and apoptosis of RGCs and accelerating the progression of DR.
Indexed as
Identifiers
40464812What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.